Introductory Chapter: Updates on the Management of Hepatocellular Carcinoma by Gomaa, Asmaa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Introductory Chapter: Updates on the Management of
Hepatocellular Carcinoma
Asmaa Gomaa, Alzhraa Alkhatib, Shimaa Alkilany,
Osama Lotfy El Abd, Hesham Abdeldayem and
Imam Waked
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67557
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Asmaa Gomaa, Alzhraa Alkhatib, Shimaa 
Alkilany, Osama Lotfy El Abd, Hesham 
Abdeldayem and Imam Waked
Additional information is available at the end of the chapter
1. Introduction
Due to many factors, such as the frequent coexistence of chronic liver disease, the wide hetero-
geneity in HCC presentation, increased available therapeutic options with diverse responses 
to these therapies in addition to the variable biologic behavior of the tumor, it is crucial to 
manage HCC patients by multidisciplinary team [1–3].
2. Early stage HCC
Only 15–30% of patients present in early stage HCC and can receive curative treatments [4]. 
This is mainly due to liver cirrhosis associated with hepatocarcinoma, and the late presentation 
reported in most patients.
2.1. Resection
Surgical resection is the best treatment option for solitary tumors in patients without cirrhosis 
with postresection 5-year survival rates of 41–74% [5, 6]. A cirrhotic liver loses its regenerative 
potential and has less functional reserve [7, 8]. The best outcome after resection is achieved in 
cirrhotic patients with well-compensated Child-Pugh class-A cirrhosis, normal bilirubin, and 
no portal hypertension [20]. Poor prognosis is influenced by pathological findings, such as 
vascular invasion, presence of satellites, and poor differentiation. Anatomic resection margins 
of 2 cm are recommended as it provides better survival outcome than narrow resection mar-
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gins <1 cm, provided that appropriate remnant liver volume is maintained [9]. The minimal 
critical remnant liver volume for resection is approximately 25% (15–40%) for noncirrhotic 
and 50% (25–90%) for cirrhotic livers. Preoperative portal vein embolization (PVE) is recom-
mended when the estimated remnant liver volume unmet the minimal requirement.
Portal hypertension, hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, was found to be 
the best predictor of postoperative liver decompensation and poor long-term outcomes in 
compensated cirrhotic patients undergoing hepatic resection [10]. Postresection tumor recur-
rences often have multifocal presentations and repeat resections are rarely ideal, instead, sal-
vage liver transplantation, or other loco-regional therapies, with or without oral multi-kinase 
inhibitors are more suitable. Molecular biomarkers and gene signatures [11] can be used for 
better selection of patients for hepatic resection with low risk for late recurrence.
2.2. Liver transplantation (LTx)
LTx is a potentially curative treatment and the best treatment option for patients with decom-
pensated cirrhosis, and it allows the removal of the primary tumor and treats hepatic insuf-
ficiency by removing cirrhotic tissue simultaneously [12]. In an attempt to identify the most 
appropriate transplant patients, the Milan criteria have emerged as main inclusion criteria 
for LTx. LTx is recommended for the patients with single lesion not larger than 5 cm, or up to 
three lesions with each less than or equal 3 cm. Restriction to Milan criteria is compatible with 
early BCLC stage and results in a 5-year overall survival rate of 75% with a risk of recurrence 
less than 15% in specialized liver transplantation centers. The perioperative mortality and 
1-year mortality are expected to be approximately 3 and ≤10%, respectively [5]. Milan criteria 
was found to be an independent prognostic factor for outcome after liver transplantation with 
5-year survival rate similar to non-HCC patients (65–78%) [13].
MELD score, initially proposed for prediction of early mortality in patients with cirrhosis, 
is the standard method to prioritize assignment of cirrhotic patients to the LTx waiting list. 
However, the MELD score is not able to predict the drop-out rate and mortality in the patient 
with HCC; therefore, a “MELD exception” has been developed to assign extra points to the 
HCC patients on the basis of the tumor burden leading to increased percentage of LTx (30–40%) 
performed for HCC [14, 15]. Several priority scores have been assigned to these patients. 
Early proposals assigned 24 and 29 points to single <2 cm and single 2–5 cm or three nodules 
each <3 cm, respectively. In the current era, no extra points and 22 points are assigned to 
those patients, respectively. Several studies have investigated the effect of expanding the 
Milan criteria, the University of California San Francisco (UCSF) proposed criteria for LTx 
for HCC (one tumor ≤6.5 cm or up to three nodules with the largest ≤4.5 cm, and the total 
tumor diameter ≤8 cm). These criteria have been prospectively and retrospectively validate 
with an overall survival comparable to those within Milan criteria [16]. Modest expansion 
of Milan criteria to “up-to-seven” criteria was proposed. This pathology-based proposal 
(HCCs having the number 7 as the sum of the size of the largest tumor and the number of 
tumors in patients without microvascular invasion) [17] has been externally validated in 
an independent series [18] but requires prospective validation studies using pretransplant 
radiolog.
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2.3. Local ablative therapy
Tumor ablation techniques induce their therapeutic effect by destroying tumor cells, either 
directly by exposing tumor cells to chemical substances (ethanol or acetic acid) or physically 
by modifying the temperature (heating or cooling).
2.4. Percutaneous ethanol injection (PEI)
PEI has been considered the most appropriate technique utilized for many years owing to its 
impacts on the natural history of HCC as shown in several studies. The major limitation of 
PEI is the high incidence of local recurrence (33–43%). PEI is indicated for the treatment of 
nodular-type HCC up to 5 cm and achieves complete necrosis in 50–90% of tumors 2–5 cm.
2.5. Radiofrequency ablation (RFA)
In the last decade, RFA appears to be superior to all other local ablative therapies and is now 
the first-line technique for ablation [19]. RFA is considered the standard of care for patients 
with very early and early stage tumors not suitable for or refusing surgery. Patients with Child-
Pugh class A and tumor size of less than or equal 3 cm in diameter undergoing percutaneous 
ablation had the best prognosis [20]. RFA depends on energy production, via utilization of 
elevated frequency alternated currents, through an electrode inserted directly into the tumor 
that induces coagulative necrosis of the tumor with safety margins of the apparently healthy 
tissue around the lesion. RFA is less invasive, less expensive with lower complication rates and 
shorter hospital stay than surgical resection (Figure 1). However, RFA is size-dependent. RFA 
can produce a necrotic area of about 4 cm so it should be considered the first option for the 
treatment of small HCC measuring up to 3 cm. With development of technology, the use of 
Figure 1. Above, left to right: Triphasic CT scan revealed enhancing right lobe focal lesion (segment VII) showing 
washout in the portovenous phase and in the delayed phase. Below, left to right: Post-RFA triphasic CT scan obtained 1 
month later revealed complete necrosis with no residual enhancing tumor.
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expandable tipped or cool-tip electrodes will achieve ablation of areas 5 cm or more in diameter 
effectively. Bipolar RF electrodes can create a larger (up to 8.4 cm) ablation in a short time [21].
2.6. Microwave ablation
Microwave ablation (MWA) is an emerging form of thermal ablation, alternative to RFA, evalu-
ated for the treatment of HCC using electromagnetic waves with frequencies greater than 900 kHz 
[22]. MWA utilizes active ablation heating, enables continuous and uniform ablation, permit-
ting generation of higher temperatures and larger ablation zones, thus leading to higher rates of 
tumor necrosis. Another advantage of MWA over RFA is that treatment outcome overcomes the 
“heat-sink” effect of vessels proximal to the tumor which can lead to incomplete ablation.
3. Intermediate stage HCC
3.1. Transarterial therapies
Transarterial therapies include TACE, transarterial embolization (TAE), transarterial bland 
embolization, transarterial chemotherapy, and transarterial radioembolization [23, 24]. 
TACE is currently considered the standard of care for patients with large multifocal lesions 
with compensated liver function, without evidence of vascular invasion or extra hepatic 
spread; however, TACE is recommended in Japan for HCC patients with vascular invasion 
if radiological portal invasion (Vp) is Vp1 or Vp2; distal to, or in the second-order branches 
of, the portal vein [25]. Success of TACE is controlled by the maximum and sustained reten-
tion of the chemical agent used (Figure 2). Lipiodol has been widely used in TACE protocols 
due to the great hunger of HCC to lipiodol. However, there is no data validated the effect of 
lipiodol in achieving slow release of the chemotherapeutic agents leading to sustained con-
centration of chemotherapeutic agents in tumor. Moreover, this can be achieved by the use 
of embolic microspheres which have the ability to sequester chemotherapeutic agents and 
release them in a controlled manner over a 1-week period and a subsequent increase of the 
local concentration of the drug with minimal systemic toxicity. Occurrence of complications 
after TACE may be related to more extensive disease; requiring nonselective embolization, 
and poor liver reserve. Selection of patients is mandatory to prevent post-TACE-induced 
liver failure. For example, patients with total bilirubin >3 mg/dL were excluded from TACE 
in several studies. MELD score can be used to select best candidates for TACE [26].
3.2. TACE with drug-eluting beads
Special particles of various sizes (from 100 to 1000 μm) can be used with the characteristic not 
only of embolizing the tumor but also of releasing substances overtime (up to 30 days) that 
determine antiblastic necrosis. Embolic microspheres have the ability to actively sequester 
chemotherapeutic agents as doxorubicin hydrochloride from solution and release them in a 
controlled fashion over a 1-week period. The use of embolic microspheres has been shown 
to substantially diminish the amount of the chemotherapeutic agent that reaches the sys-
temic circulation, increase the local concentration of the drug, and the antitumor efficacy 
with negligible systemic toxicity. Tolerance to conventional TACE has improved by the use 
of drug-eluting beads that obstruct arterial vessels and slowly release chemotherapy [27].
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3.3. Radioembolization
Selective internal radiation therapy (SIRT) has been emerged as a therapeutic option for inter-
mediate-stage HCC. SIRT aims to selectively target radiation to liver tumors while limiting 
the dose to normal liver parenchyma, thus preventing ischemia to the liver tissue, SIRT exerts 
its effect through deposition of yttrium-90 ((90)Y) microspheres into the hepatic artery that 
feed the tumor in a 3:1 to 20:1 ratio compared with a normal liver, so that tumor nodules are 
treated irrespective of their number, size, or location [28].
4. Advanced stage HCC
4.1. Systemic therapy
Systemic therapy with hormonal agents such as octreotide and tamoxifen or with biological 
agents as interferon therapy [29], and thalidomide showed poor results.
Systemic chemotherapy showed contradictory results. HCC is one of the most chemo-resis-
tant tumors; in addition, chemotherapy is poorly tolerated by patients with liver cirrhosis 
because of major side effects. Hence, no systemic chemotherapy was recommended for 
patients with advanced tumors. Cytotoxic agents such as 5-fluorouracil, cisplatin, doxorubi-
cin, gemcitabine, capecitabin, and epirubicin or combined regimens showed a low response 
rate (<10%) with only marginal improvements in overall survival [30]. Cisplatin, interferon, 
doxorubicin, and fluorouracil (PIAF) used in combination showed promising activity in a 
phase II study but not in phase III. Moreover, patients treated with the PIAF regimen experi-
enced significantly higher rate of myelotoxicity compared with doxorubicin.
4.2. Molecular targeted therapy
Hepatocarcinogenesis is associated with epigenetic and genetic alterations that eventually lead to 
an alteration in the molecular pathways resulting in uncontrolled growth of the hepatocytes [31].
Figure 2. Left: Triphasic CT scan revealed enhancing right lobe focal lesion in the arterial phase. Right: Post TACE 
triphasic CT scan obtained 1 month showed complete cure.
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4.2.1. Sorafenib
Multiple cellular kinases are involved in the development and progression of the HCC through 
induction of angiogenesis and cellular proliferation. Overexpression of surface tyrosine kinases 
or mutational activation of Ras oncogene leads to Ras/MAPK pathway activation, an important 
step in HCC proliferation and angiogenesis. Sorafenib is an orally administered multikinase 
inhibitor drug, inhibits vascular endothelial growth factor receptor (VEGFR)- (VEGFR-) 1, 
VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), Ras/MAPK pathway, 
involving Raf-1 (C-Raf) and B-Raf (wild and mutant types), FMS-like tyrosine kinase-3 (Flt), 
and c-kit with antiproliferative and antiangiogenic activity [32, 33]. The European guidelines 
recommended sorafenib for unresectable, advanced, Child–Pugh class A or B HCC with PS 0–2 
and vascular invasion or distant metastasis [5]. According to the Japanese guidelines, sorafenib 
is recommended for unresectable, advanced, Child–Pugh class A HCC with vascular invasion 
or distant metastasis, as well as for patients intolerant to TACE or in whom the procedure of 
TACE is technically difficult [34]. Sorafenib was generally well tolerated with mild toxicity, 
predominantly including diarrhea, fatigue, weight loss, rash, or superficial skin desquamation 
and hand-foot skin reaction, hair loss, anorexia, nausea, and abdominal pain.
4.2.2. Molecular targeted agents other than sorafenib
Since the survival benefit achieved with sorafenib (compared to placebo) was minimal, search 
for alternative therapies was mandatory. Other targeted agents in phase III trials revealed 
nonsuperior results of antiangiogenic tyrosine kinase inhibitors (TKI) sunitinib, linifanib, 
brivanib, or the combination of sorafenib with erlotinib [35] for sorafenib-naive advanced 
HCC patients compared to sorafenib and none have exceeded the benefits of sorafenib, in 
addition, brivanib [36], ramucirumab [37], and everolimus [38] have been tested as second 
line, in patients who were refractory or intolerant to first-line treatment with sorafenib, with 
no significant improvement in overall survival, although TTP was significantly longer in 
the brivanib arm than with placebo. A decision-making process is required to tailor first-
line medical treatment with sorafenib in the advanced stage. This should include nutritional, 
functional, and comorbidity status of the patient.
Author details
Asmaa Gomaa1,2, Alzhraa Alkhatib1, Shimaa Alkilany1, Osama Lotfy El Abd3, Hesham 
Abdeldayem4,* and Imam Waked1,2
*Address all correspondence to: habdeldayem64@hotmail.com
1 Department of Oncology, National Liver Institute, Menoufia University, Egypt
2 Department of Hepatology, National Liver Institute, Menoufia University, Egypt
3 Department of Radiology, National Liver Institute, Menoufia University, Egypt
4 Department of Surgery, National Liver Institute, Menoufia University, Egypt
Updates in Liver Cancer6
References
[1] Bruix, J., G.J. Gores, and V. Mazzaferro, Hepatocellular carcinoma: clinical frontiers and per-
spectives. Gut, 2014. 63(5): pp. 844–55.
[2] Guy, J., et al., Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol 
Hepatol, 2012. 10(4): pp. 354–62.
[3] Kaseb, A.O., Y.M. Abaza, and R.E. Roses, Multidisciplinary management of hepatocellular 
carcinoma. Recent Results Cancer Res, 2013. 190: pp. 247–59.
[4] Finn, R.S., Development of molecularly targeted therapies in hepatocellular carcinoma: where do 
we go now? Clin Cancer Res, 2010. 16(2): pp. 390–7.
[5] Arii, S., et al., Results of surgical and nonsurgical treatment for small-sized hepatocellular carci-
nomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. 
Hepatology, 2000. 32(6): pp. 1224–9.
[6] Grazi, G.L., et al., Improved results of liver resection for hepatocellular carcinoma on cirrhosis 
give the procedure added value. Ann Surg, 2001. 234(1): pp. 71–8.
[7] Beard, R.E., et al., A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocel-
lular carcinoma patients in a Western institution. Surgery, 2013. 154(3): pp. 545–55.
[8] Bhoori, S., et al., First-line treatment for hepatocellular carcinoma: resection or transplantation? 
Transplant Proc, 2007. 39(7): pp. 2271–3.
[9] Forner, A., et al., Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective vali-
dation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology, 2008. 
47(1): pp. 97–104.
[10] Shi, M., et al., Partial hepatectomy with wide versus narrow resection margin for solitary hepa-
tocellular carcinoma: a prospective randomized trial. Ann Surg, 2007. 245(1): pp. 36–43.
[11] Bruix, J. and M. Sherman, Management of hepatocellular carcinoma: an update. Hepatology, 
2011. 53(3): pp. 1020–2.
[12] Nault, J.C., et al., A hepatocellular carcinoma 5-gene score associated with survival of patients 
after liver resection. Gastroenterology, 2013. 145(1): pp. 176–87.
[13] Mazzaferro, V., et al., Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol, 
2008. 15(4): pp. 1001–7.
[14] Raia, S., J.R. Nery, and S. Mies, Liver transplantation from live donors. Lancet, 1989. 2(8661): 
p. 497.
[15] Mazzaferro, V., et al., Milan criteria in liver transplantation for hepatocellular carcinoma: an 
evidence-based analysis of 15 years of experience. Liver Transpl, 2011. 17(2): p. 22365.
[16] Taniguchi, M., Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry. 
Clin Transpl, 2012: p. 41–65.
Introductory Chapter: Updates on the Management of Hepatocellular Carcinoma
http://dx.doi.org/10.5772/67557
7
[17] Raza, A. and G.K. Sood, Hepatocellular carcinoma review: current treatment, and evidence-
based medicine. World J Gastroenterol, 2014. 20(15): pp. 4115–27.
[18] Yao, F.Y., et al., Excellent outcome following down-staging of hepatocellular carcinoma prior 
to liver transplantation: an intention-to-treat analysis. Hepatology, 2008. 48(3): pp. 819–27.
[19] Ravaioli, M., et al., Liver transplantation for hepatocellular carcinoma: results of down-staging 
in patients initially outside the Milan selection criteria. Am J Transplant, 2008. 8(12): pp. 
2547–57.
[20] Yao, F.Y., et al., Liver transplantation for hepatocellular carcinoma: validation of the UCSF-
expanded criteria based on preoperative imaging. Am J Transplant, 2007. 7(11): pp. 2587–96.
[21] Mazzaferro, V., et al., Predicting survival after liver transplantation in patients with hepatocel-
lular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol, 
2009. 10(1): pp. 35–43.
[22] Raj, A., J. McCall, and E. Gane, Validation of the “Metroticket” predictor in a cohort of patients 
transplanted for predominantly HBV-related hepatocellular carcinoma. J Hepatol, 2011. 55(5): 
pp. 1063–8.
[23] Lencioni, R., Loco-regional treatment of hepatocellular carcinoma. Hepatology, 2010. 52(2): 
pp. 762–73.
[24] Roskams, T. and M. Kojiro, Pathology of early hepatocellular carcinoma: conventional and 
molecular diagnosis. Semin Liver Dis, 2010. 30(1): pp. 17–25.
[25] Lin, S.M., Recent advances in radiofrequency ablation in the treatment of hepatocellular carci-
noma and metastatic liver cancers. Chang Gung Med J, 2009. 32(1): pp. 22–32.
[26] Martin, R.C., C.R. Scoggins, and K.M. McMasters, Safety and efficacy of microwave ablation 
of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol, 2010. 17(1): 
pp. 171–8.
[27] Tsochatzis, E.A., G. Germani, and A.K. Burroughs, Transarterial chemoembolization, tran-
sarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. 
Semin Oncol, 2010. 37(2): pp. 89–93.
[28] Lin, S., K. Hoffmann, and P. Schemmer, Treatment of hepatocellular carcinoma: a systematic 
review. Liver Cancer, 2012. 1(3–4): pp. 144–58.
[29] Yeo, W., et al., A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-
2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular 
carcinoma. J Natl Cancer Inst, 2005. 97(20): pp. 1532–8.
[30] Fuchs, C.S., et al., A phase II trial of gemcitabine in patients with advanced hepatocellular car-
cinoma. Cancer, 2002. 94(12): pp. 3186–91.
[31] Cervello, M., et al., Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 
Oncotarget, 2012. 3(3): pp. 236–60.
Updates in Liver Cancer8
[32] Forner, A., J.M. Llovet, and J. Bruix, Chemoembolization for intermediate HCC: is there proof 
of survival benefit? J Hepatol, 2012. 56(4): pp. 984–6.
[33] Chang, Y.S., et al., Sorafenib (BAY 43–9006) inhibits tumor growth and vascularization and 
induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol, 
2007. 59(5): pp. 561–74.
[34] Kudo, M., K. Ueshima, and T. Arizumi, Real-life clinical practice with sorafenib in advanced 
hepatocellular carcinoma: a single-center experience. Dig Dis, 2012. 30(6): pp. 609–16.
[35] Zhu, A.X., et al., SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of 
sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 2015. 
33(6): pp. 559–66.
[36] Llovet, J.M., et al., Brivanib in patients with advanced hepatocellular carcinoma who were intol-
erant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS 
study. J Clin Oncol, 2013. 31(28): pp. 3509–16.
[37] Zhu, A., et al., Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced 
hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: results from the ran-
domized phase III REACH study. Ann Oncol, 2014. 25: pp. v1–v41.
[38] Zhu, A.X., et al., Effect of everolimus on survival in advanced hepatocellular carcinoma after 
failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA, 2014. 312(1): pp. 57–67.
Introductory Chapter: Updates on the Management of Hepatocellular Carcinoma
http://dx.doi.org/10.5772/67557
9

